Published in Managed Care Business Week, August 21st, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Merck & Co., Inc.
Report 1: Late breaking data presented at the American Diabetes Association (ADA) 67th Annual Scientific Sessions showed that, when used investigationally as initial therapy, JANUVIA(TM) (sitagliptin) in combination with metformin provided significant glycemic improvement and was generally well tolerated over 54 weeks in patients with type 2 diabetes. Additional new data from investigational studies presented also showed that JANUVIA significantly improved blood sugar...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Managed Care Business Week